308 related articles for article (PubMed ID: 38310228)
21. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
22. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
23. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation.
Park JH; Lee NK; Lee SY
Mol Cells; 2017 Oct; 40(10):706-713. PubMed ID: 29047262
[TBL] [Abstract][Full Text] [Related]
24. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
25. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
26. The STING inhibitor C-176 attenuates osteoclast-related osteolytic diseases by inhibiting osteoclast differentiation.
Yu ZC; Fu R; Li Y; Zhao DY; Jiang H; Han D
FASEB J; 2023 Apr; 37(4):e22867. PubMed ID: 36906288
[TBL] [Abstract][Full Text] [Related]
27. Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis.
Gu R; Santos LL; Ngo D; Fan H; Singh PP; Fingerle-Rowson G; Bucala R; Xu J; Quinn JM; Morand EF
Cytokine; 2015 Apr; 72(2):135-45. PubMed ID: 25647268
[TBL] [Abstract][Full Text] [Related]
28. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation.
Fuji H; Ohmae S; Noma N; Takeiri M; Yasutomi H; Izumi K; Ito M; Toyomoto M; Iwaki S; Takemoto K; Seo S; Taura K; Hida S; Aoyama M; Ishihama Y; Hagiwara M; Takeda N; Hatano E; Iwaisako K; Uemoto S; Asagiri M
Biochem Biophys Res Commun; 2018 Sep; 503(2):544-549. PubMed ID: 29800570
[TBL] [Abstract][Full Text] [Related]
29. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
31. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
[TBL] [Abstract][Full Text] [Related]
32. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
[TBL] [Abstract][Full Text] [Related]
33. Roburic acid attenuates osteoclastogenesis and bone resorption by targeting RANKL-induced intracellular signaling pathways.
Wang G; Chen K; Ma C; Wang C; Chen D; He J; Liu Y; Jiang T; Yuan J; Chen L; He W; Xu J
J Cell Physiol; 2022 Mar; 237(3):1790-1803. PubMed ID: 34796915
[TBL] [Abstract][Full Text] [Related]
34. Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.
Meng J; Zhou C; Zhang W; Wang W; He B; Hu B; Jiang G; Wang Y; Hong J; Li S; He J; Yan S; Yan W
J Cell Mol Med; 2019 Oct; 23(10):6730-6743. PubMed ID: 31328430
[TBL] [Abstract][Full Text] [Related]
35. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
Cheng CP; Sheu MJ; Sytwu HK; Chang DM
Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
[TBL] [Abstract][Full Text] [Related]
36. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.
Yamashita T; Uehara S; Udagawa N; Li F; Kadota S; Esumi H; Kobayashi Y; Takahashi N
PLoS One; 2014; 9(1):e85878. PubMed ID: 24465763
[TBL] [Abstract][Full Text] [Related]
37. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
39. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation.
Nishikawa K; Nakashima T; Hayashi M; Fukunaga T; Kato S; Kodama T; Takahashi S; Calame K; Takayanagi H
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3117-22. PubMed ID: 20133620
[TBL] [Abstract][Full Text] [Related]
40. Predicting the targets of IRF8 and NFATc1 during osteoclast differentiation using the machine learning method framework cTAP.
Wang H; Joshi P; Hong SH; Maye PF; Rowe DW; Shin DG
BMC Genomics; 2022 Jan; 23(1):14. PubMed ID: 34991467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
